Roche Holding AG (TSX:ROG)
Canada · Delayed Price · Currency is CAD | Market Cap | 485.13B +32.9% |
| Revenue (ttm) | 110.65B -0.8% |
| Net Income | 21.69B +30.9% |
| EPS | 26.95 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.37 |
| Forward PE | 16.85 |
| Dividend | 0.77 (2.67%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 10,300 |
| Open | 28.62 |
| Previous Close | 28.80 |
| Day's Range | 28.62 - 28.70 |
| 52-Week Range | 20.03 - 29.87 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
Roche (RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Ocrevus intravenous infusion for the treatment of pediatric ...
CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis
Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the appro...
Roche, Genentech Expand U.S. Research Footprint With New Boston Center
(RTTNews) - Roche Holding AG (RHHBY) announced the opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in one of the world's leading life scie...
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today celebrated the grand opening of the Roche Genentech Innovation Cente...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in...
Dualitas Therapeutics, Roche Partner On Bispecific Antibody Research
(RTTNews) - Dualitas Therapeutics, Inc., a biotechnology company developing next-generation bispecific antibody therapies, announced a research collaboration and license agreement with Roche Holding A...
RHHBY Looks 34.1% Overvalued on GF Value™ as Dividend Sustainability Remains Key
RHHBY Looks 34.1% Overvalued on GF Value™ as Dividend Sustainability Remains Key
Genentech reports CELESTIMO study meets primary endpoint
Genentech, a member of Roche (RHHBY), announced that the Phase III CELESTIMO study evaluating Lunsumio in combination with lenalidomide versus Rituxan plus lenalidomide in people with relapsed or refr...
Roche's Lunsumio Shows Improved OS And PFS In Comparative Study For Follicular Lymphoma
(RTTNews) - Roche Holdings AG (RHHBY), a biopharmaceutical company, on Thursday announced that the Phase 3 CELESTIMO trial for Lunsumio plus lenalidomide had met its primary endpoint in a comparative ...
Genentech's Lunsumio-based Regimen Meets Primary Goal In Phase III Study In Follicular Lymphoma
(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), on Thursday announced that its Lunsumio-based regimen significantly improved progression-free survival in...
Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/...
Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzuma...
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.
Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation
[The content of this article has been produced by our advertising partner.] Healthcare professionals and technology innovators are transforming how diseases are detected, managed, and treated—shifting...
Roche Collaborator MediLink Says Tam-Peli Achieves 54% OS Risk Reduction In Phase III SCLC Trial
(RTTNews) - Roche (RHHBY) announced that its collaborator MediLink released interim results from the randomized Phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus top...
Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint
Roche (RHHBY) announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli versus topotecan in Chinese patients with relapsed s...
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Pel...
Roche price target raised to CHF 380 from CHF 365 at HSBC
HSBC raised the firm’s price target on Roche (RHHBY) to CHF 380 from CHF 365 and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
Genentech granted Priority Review for Enspryng sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted Priority Review to a supplemental biologics license application, or sBLA, for Enspryng for the treatment of myelin oligodendroc...
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Applicati...
Roche initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Roche (RHHBY) with an Outperform rating and CHF 400 price target The near-to-mid-term the base business is gaining momentum, while the pipeline “offers deeper potenti...
A Prevention Prescription for Hong Kong
Roche Diagnostics Hong Kong general manager Ronald Lo is pushing the city beyond reactive medicine towards a prevention-led system powered by automation, AI and empowered patients. For Ronald Lo, diag...
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-1...